Role for the Kunitz-3 Domain of Tissue Factor Pathway Inhibitor-α in Cell Surface Binding
- 7 December 2004
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 110 (23) , 3567-3572
- https://doi.org/10.1161/01.cir.0000148778.76917.89
Abstract
Background— Tissue factor pathway inhibitor (TFPI)-α, a key regulator of tissue factor–induced coagulation, contains 3 tandem Kunitz-type inhibitory domains. Kunitz-1 binds and inhibits factor VIIa in the factor VIIa/tissue factor complex, and Kunitz-2 binds and inhibits factor Xa. The role of the Kunitz-3 domain of TFPI-α, however, has remained an enigma. Methods and Results— To determine the structures within TFPI-α involved in its binding to cell surface, altered forms of TFPI-α were expressed in C127 (mouse mammary) cells: C-terminal truncated forms TFPI-α (252), TFPI-α (242), and TFPI-α (181), which also lacks the third Kunitz domain (K3); TFPI-α (desK3), which lacks only the K3 domain; and TFPI-α (R199L), in which the putative P1 site in K3 is changed from arginine to leucine. By flow cytometry (fluorescence-activated cell sorting), the altered forms 252, 242, and R199L showed significantly reduced binding, whereas the forms 181 and desK3 completely failed to bind to the cell surface. Transient expression of WT-, desK3-, and K3/K2-TFPI-α (in which K3 is replaced with K2) in another cell line (b-end3, mouse endothelial) produced comparable results. Exogenously added C-terminal truncated and R199L forms of TFPI-α bound poorly and desK3 did not bind at all to the surface of ECV304 cells in which TFPI-α expression had been “knocked down” by RNA interference. Conclusions— Optimal cell binding of endogenously expressed TFPI-α requires its K3 and C-terminal domains, and within the K3 domain, the P1 (R199) residue plays an important role. Thus, one role of the K3 domain involves the cell surface localization of TFPI-α.Keywords
This publication has 18 references indexed in Scilit:
- Glycosyl Phosphatidylinositol Anchorage of Tissue Factor Pathway InhibitorCirculation, 2003
- Regulation of Functions of Vascular Wall Cells by Tissue Factor Pathway InhibitorArteriosclerosis, Thrombosis, and Vascular Biology, 2002
- Ligand-induced protease receptor translocation into caveolae: a mechanism for regulating cell surface proteolysis of the tissue factor-dependent coagulation pathway.The Journal of cell biology, 1996
- Inhibitory Properties of Separate Recombinant Kunitz‐Type‐Protease‐Inhibitor Domains from Tissue‐Factor‐Pathway InhibitorEuropean Journal of Biochemistry, 1996
- Thrombin Induces the Redistribution and Acute Release of Tissue Factor Pathway Inhibitor From Specific Granules Within Human Endothelial Cells in CultureArteriosclerosis, Thrombosis, and Vascular Biology, 1995
- Structural requirements for tissue factor pathway inhibitor interactions with factor Xa and heparinBlood Coagulation & Fibrinolysis, 1993
- Cultured normal human hepatocytes do not synthesize lipoprotein-associated coagulation inhibitor: evidence that endothelium is the principal site of its synthesis.Proceedings of the National Academy of Sciences, 1990
- Identification of the 1.4 KB and 4.0 KB messages for the lipoprotein associated coagulation inhibitor and expression of the encoded proteinThrombosis Research, 1989
- Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitorNature, 1989
- Heparin induces release of extrinsic: Coagulation pathway inhibitor (EPI)Thrombosis Research, 1988